NOREPINEPHRINE BITARTRATE
| Brand name | NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE |
|---|---|
| Active ingredient | NOREPINEPHRINE BITARTRATE |
| Strength | EQ 4MG BASE/250ML (EQ 16MCG BASE/ML) |
| Dosage form | SOLUTION |
| Route | INTRAVENOUS |
| Modality | Small molecule |
| FDA approval | October 2022 |
| Marketing status | RX |
| Patent | Expires | Type |
|---|---|---|
| 11413259 | January 2038 | product |
| 10420735 | January 2038 | product |
| 10226436 | January 2038 | product |
| 12245996 | January 2038 | product |
| 10568850 | January 2038 | product |
| 10159657 | January 2038 | product |
| 11602508 | January 2038 | product |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.